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Abstract
The CD94 transmembrane-anchored glycoprotein forms disulfide-bonded heterodimers with the NKG2A subunit to form an
inhibitory receptor or with the NKG2C or NKG2E subunits to assemble a receptor complex with activating DAP12 signaling
proteins. CD94 receptors expressed on human and mouse NK cells and T cells have been proposed to be important in NK
cell tolerance to self, play an important role in NK cell development, and contribute to NK cell-mediated immunity to certain
infections including human cytomegalovirus. We generated a gene-targeted CD94-deficient mouse to understand the role
of CD94 receptors in NK cell biology. CD94-deficient NK cells develop normally and efficiently kill NK cell-susceptible targets.
Lack of these CD94 receptors does not alter control of mouse cytomegalovirus, lymphocytic choriomeningitis virus, vaccinia
virus, or Listeria monocytogenes. Thus, the expression of CD94 and its associated NKG2A, NKG2C, and NKG2E subunits is
dispensable for NK cell development, education, and many NK cell functions.
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Introduction
Natural killer (NK) cells play an important role in the innate
immune response to infections and malignancies by directly killing
pathogen-infected or transformed cells and producing cytokines and
chemokines that help shape the immune response [1]. NK cell
activation is controlled by a number of activating and inhibitory
receptors [2]. Activating NK receptors recognize a variety of stress-
induced molecules such as the human MICA and MICB molecules,
human ULBP1-6 proteins, mouse Rae-1, H60, and MULT1 family
members, all of which are recognized by the activating NKG2D
receptor [3]. Some activating NK receptors directly recognize
pathogen-encoded ligands. For example, the m157 glycoprotein
expressed by MCMV is recognized by the activating Ly49H
receptor and NKp46 interacts with influenza hemagglutinin [4,5,6].
NK cells are prevented from attacking normal self cells by inhibitory
receptors that are reactive to MHC class I [7].
In mice, the inhibitory members of the Ly49 C-type lectin-like
receptor family of NK cell receptors are the primary MHC class I
receptors [8]. Humans do not express Ly49 receptors; instead,
human NK cells express the structurally unrelated inhibitory killer
cell immunoglobulin-like receptors (KIRs) that bind to MHC class
I. Additionally, humans and mice both express members of the
NKG2 family receptors that form obligate disulfide-bonded
heterodimers with CD94. When expressed at physiological levels,
the human NKG2 proteins cannot be stably expressed on the cell
surface without CD94 [9,10,11]. CD94-NKG2 receptors bind
non-classical MHC class Ib molecules, HLA-E in humans and Qa-
1 in mice [12,13,14]. HLA-E and Qa-1 both present conserved
peptides derived from the leader segments of classical MHC class I
molecules [12,15]. Both human and murine NKG2 families
consist of three members that share a high degree of similarity in
their extracellular domains, NKG2A, NKG2C, and NKG2E
[13,16,17,18]. NKG2D is an unrelated receptor that does not pair
with CD94 and has low sequence homology with NKG2A,
NKG2C, and NKG2E [19].
In adult mice, CD94 is expressed on splenic NK cells and NKT
cells and a small proportion of cd T cells and CD8+ T cells,
primarily CD44hi memory cells. In mouse NK cells, NKG2A is the
predominant NKG2 family member with NKG2A mRNA being
more prevalent than NKG2C and NKG2E transcripts [17].
NKG2A is the only NKG2 family member expressed in mouse T
cells [17]. The cytoplasmic domain of NKG2A contains one
canonical immunoreceptor tyrosine-based inhibitory motif (ITIM)
in mice and two ITIMs in human [9,13,20,21]. Accordingly,
triggering of CD94-NKG2A suppresses NK cell functions.
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NKG2C and NKG2E lack known intracellular signaling domains,
but instead contain a charged residue within their transmembrane
domains that facilitate binding to the DAP12 signaling adapter
molecule, which contains an immunoreceptor tyrosine based
activating motif (ITAM) [16]. Triggering of CD94-NKG2C leads
to phosphorylation of the DAP12 ITAM and signaling via Syk and
ZAP-70, resulting in NK cell activation [20,21]. As with other
paired inhibitory and activating ligands, the affinity for HLA-E is
10-fold higher for the inhibitory human CD94-NKG2A than the
activating CD94-NKG2C receptor [22,23]. The affinities of the
mouse CD94-NKG2 receptors for Qa-1 have not been reported.
To better understand the role of CD94-NKG2 receptors in NK
cell development and function we disrupted the gene encoding
CD94 (Klrd1) in the genome of 129/SvJ strain ES cells, generated
mice lacking CD94, and backcrossed this CD94-deficient mouse
onto the C57BL/6 background. Additionally, we generated a
CD94 transgenic mouse that was crossed with the CD94-deficient
mice to restore the expression of CD94-NKG2A, CD94-NKG2C,
and CD94-NKG2E receptors in the Klrd12/2 mice to evaluate the
role of these receptors in NK cell development and function.
Results
Generation and phenotype of CD94-deficient mice
To understand the contribution of CD94 receptors to NK cell
and T cell functions we generated a CD94-deficient mouse by
targeted disruption of exons 3 and 4 of Klrd1 in 129/SvJ ES cells and
backcrossing the null gene into the genome of C57BL/6 mice.
Splenocytes from CD94-deficient mice failed to express the CD94-
NKG2A, CD94-NKG2C, or CD94-NKG2E receptors (Fig. 1A).
Transgenic expression of CD94 in these CD94-deficient mice
(designated CD94Tg/– mice) restored expression of CD94-NKG2A,
CD94-NKG2C, and CD94-NKG2E (Fig. 1A). Although a MHC
class I promoter with an Igm enhancer drove the CD94 transgene
[24], CD94 was expressed at the highest levels on NKp46+ NK cells
(Fig. 1A). Similar to B6 mice, the majority of the remaining CD94-
NKG2-expressing cells from CD94Tg/– mice were NKT cells and T
cells (Fig 1A). CD94Tg/– splenocytes did show an increased intensity
of CD94 staining as determined by mean fluorescence intensity
(MFI) on the NKG2A/C/E– cells as compared to B6, CD94-
deficient, and 129/SvJ splenocytes (MFI 4433, 625, 492, and 1013,
respectively) (Fig. 1A). NKG2A/C/E expression levels, as deter-
mined by staining with an antibody that crossreacts with NKG2A,
NKG2C, and NKG2E, were consistently lower in the CD94Tg/–
splenocytes (MFI 147) when compared with B6 splenocytes (MFI
213); however, the MFI of NKG2A/C/E was similar between the
CD94Tg/– and 129/SvJ splenocytes (MFI 135), suggesting allelic
differences between the B6 and 129/SvJ genes encoding NKG2
receptors might determine the surface density of CD94-NKG2A/
C/E (Fig. 1A). Transgenic expression of CD94 restored CD94-
NKG2 expression to approximately half of the NK cells in these
mice, similar to wildtype mice (Fig. 1B). This suggests that
expression of NKG2A, NKG2C, or NKG2E, not CD94, might
be the limiting factor in CD94-NKG2 surface expression.
Klrd1 is located between the Ly49 gene cluster and the NKR-P1
gene cluster in the NK complex (NKC) found on chromosome 6
[25,26]. B6 and 129/SvJ mice carry different loci and alleles of this
genomic cluster, with NK cells from B6 mice but not 129/SvJ
mice expressing Ly49C, Ly49H, and NKR-P1C (NK1.1) [27].
NK cells from CD94-deficient mice did not express any of these
receptors, indicating that despite being backcrossed to B6 for 9
generations they retained the NKC of 129/SvJ strain mice, at least
spanning the regions containing the NKR-P1 and Ly49 loci
(Fig. 1B).
CD19– CD122+ NKG2D+ NK cell precursors undergo an
orderly development in the bone marrow that can be distinguished
based on the expression of the integrins aV (CD51) and DX5
(CD49b) [28]. aV is expressed first by NK precursors, followed by
co-expression of DX5, and finally loss of aV expression. CD94-
NKG2 receptors are initially expressed by aV
+, DX5– immature
NK cells [28]. CD27 and CD11b can also delineate NK cell
maturation stages. CD27+CD11blo NK cells are the most immature
with CD11b expression increasing as NK cells mature, and CD27 is
lost on the most mature NK cells [29]. NK cell precursors from
CD94-deficient, CD94Tg/–, and 129/SvJ mice contained similar
frequencies of each these developmental stages, indicating that
expression of CD94-NKG2 is not necessary for normal NK
development (Fig. 1C). The frequency of CD11bhi CD27– mature
NK cells was somewhat higher in the B6 mice than any of the other
strains, suggesting that a factor other than CD94-NKG2 expression
may differentially regulate NK cell development in B6 vs. 129/SvJ
mice. Frequencies and absolute numbers of splenic NK cells were
similar among B6, CD94-deficient, CD94Tg/–, and 129/SvJ mice
(data not shown).
NK cell functions are not altered in CD94-deficient mice
Expression of inhibitory receptors for self-MHC class Ia and Ib
molecules, including the Ly49 receptors and CD94-NKG2A,
enhances NK cell responsiveness to activation by crosslinking of
activating receptors [30,31,32,33]. To determine whether CD94-
deficiency affects NK cell education, we stimulated B6, CD94-
deficient, CD94Tg/–, and 129/SvJ NK cells by crosslinking the
activating NKp46 receptor. CD94-deficient, CD94Tg/–, and 129/
SvJ NK cells all produced IFN-c and degranulated at similar
frequencies as measured by CD107a surface staining (Fig. 2A).
This indicates that CD94 is not required for NK cell education in
NK cells carrying the 129/SvJ NK complex. CD94-deficient,
CD94Tg/–, and 129/SvJ NK cells all produced IFN-c and
degranulated less frequently than B6 NK cells, suggesting that
an unknown factor within the NK complex might control the
degree to which B6 and 129/SvJ NK cells are educated (Fig. 2A)
NK cells lyse target cells expressing ligands for a variety of NK
receptors, including the NKG2D receptor necessary for recogni-
tion of the prototypic NK-sensitive YAC-1 tumor cell line.
NKG2D expression was similar between B6 and CD94-deficient
NK cells (data not shown). Accordingly, NK cells from both B6
and CD94-deficient mice killed YAC-1 targets with similar
efficacy, indicating that CD94-deficiency did not affect NK cell
lytic capacity against this target cell (Fig. 2B).
NK cells are prevented from killing healthy bone marrow cells
and splenocytes by inhibitory receptors on NK cells that engage
MHC class I on these target cells. Bone marrow cells and
splenocytes from animals deficient in surface expression of MHC
class I due to deletion of the B2m, TAP1 and TAP2, or H-2Kb and
H-2Db genes are efficiently eliminated by NK cells in vivo [34,35].
To test whether CD94-NKG2 receptors were important in
‘‘missing-self’’ recognition we transferred a 1:1 mixture of wildtype
and B2m2/2 splenocytes into B6 mice depleted of NK cells or
treated with PBS or into CD94-deficient mice. Twenty-four hours
later both B6 and CD94-deficient mice efficiently eliminated the
B2m2/2 splenocytes compared to B6 mice depleted of NK cells
(Fig. 2C).
CD94-NKG2 receptors do not contribute to NK cell
control of MCMV
After MCMV infection all NK cells are activated, likely due to
the inflammatory cytokine milieu induced by the infection [36].
Despite not expressing the MCMV specific Ly49H receptor
CD94-Deficient Mice
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(Fig. 1B), CD94-deficient NK cells upregulated expression of
CD69, granzyme B, and IFN-c to a similar extent as B6 NK cells
(Fig 3A). CD94-deficient and CD94Tg/– mice were equally
susceptible to MCMV infection, suggesting that in the absence
of the Ly49H activating receptor CD94-NKG2 does not play an
important role in the control of MCMV (Fig. 3B). CD94-deficient
and CD94Tg/– NK cells express the 129/SvJ allele of the Ly49I
inhibitory receptor, which binds to MCMV m157 [6]. This
interaction may mask any effect CD94-NKG2 receptors could
have on control of MCMV. To determine whether CD94-NKG2
Figure 1. Splenic CD94-deficient and CD94Tg/– NK cells are phenotypically normal. (A) Splenocytes from B6, CD94-deficient, CD94Tg/–, and
129/SvJ mice were analyzed for CD94-NKG2 expression. CD94-NKG2+ cells were analyzed for NKp46 and TCRb expression as shown in the second
column. (B) NK cells (NKp46+ TCRb–) were analyzed for expression of CD94, NKG2A/C/E, NK1.1, Ly49C/I, and Ly49H. (C) CD19– bone marrow cells were
analyzed for NK cell precursors (NKG2D+ CD122+) and the developmental markers DX5, aV, CD27, and CD11b. Data are representative of three to five
experiments each.
doi:10.1371/journal.pone.0015184.g001
CD94-Deficient Mice
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receptors affect NK cell control in mice that express the MCMV-
specific Ly49H activating receptor we treated B6 mice either with
PBS or a non-depleting, blocking antibody that recognizes
NKG2A, NKG2C, and NKG2E. Despite saturating the CD94-
NKG2 receptors with the neutralizing antibody (data not shown),
this treatment had no effect on NK cell control of MCMV
infection in these mice (Fig. 3C). Blocking NKG2A, NKG2C, and
NKG2E also did not affect control of MCMV in the susceptible
BALB/c mice that do not express Ly49H or Ly49I (Fig. 3D). Thus
CD94-NKG2 receptors do not affect the NK cell response to
infection with the Smith strain of MCMV.
CD94-deficient mice control LCMV, vaccinia virus, and
Listeria infection as efficiently as B6 mice
To determine whether CD94-NKG2 receptors contributed to
the clearance of other infections we infected CD94-deficient and
B6 mice with LCMV, vaccinia virus or Listeria monocytogenes.
LCMV clearance was slightly delayed in the CD94-deficient mice
Figure 2. CD94-deficient NK cells are educated and efficiently kill YAC-1 targets and MHC I-deficient splenocytes. (A) Splenocytes
from B6, CD94-deficient, CD94Tg/–, and 129/SvJ mice were assayed for degranulation as measured by surface staining for CD107a and intracellular
IFN-c production upon stimulated with plate-bound anti-NKp46 mAb. (B) Splenocytes from CD94-deficient mice and wildtype 129/SvJ mice primed
with poly I:C in vivo were assayed for NK cell-mediated cytotoxicity against the YAC-1 target cell. (C) CD94-deficient mice and B6 mice either depleted
of NK cells with anti-NK1.1 mAb or treated with PBS received a mixture of CFSE-labeled wildtype and B2m2/2 B6 splenocytes. Twenty-four hours later
the frequency or CFSE-labeled donor cells in the spleen that were B2m2/2was determined by expression of H-2Kb. Data are representative of three to
five experiments each.
doi:10.1371/journal.pone.0015184.g002
CD94-Deficient Mice
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Figure 3. CD94 is not necessary for control of MCMV. (A) Two days after infection with MCMV splenic NK cells from B6 and CD94-deficient
mice were analyzed for expression of CD69 and intracellular IFN-c and granzyme B. (B) CD94-deficient and CD94Tg/– mice, (C) B6 mice treated with the
non-depleting, blocking anti-NKG2A/C/E chimeric rat-mouse monoclonal antibody 20D5HCmIgG1-Q, anti-NK1.1 depleting antibody or PBS (D), or
CD94-Deficient Mice
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with viral loads in the spleens and livers of B6 mice peaking at day
3 compared to day 5 in the CD94-deficient mice (Fig 4A).
However, differences in viral titers were not statistically significant.
Despite this delay in peak viral load, CD94-deficient mice cleared
the infection by day 13 suggesting that CD94-NKG2 does not play
a prominent role in control of LCMV infection. The role of NK
cells in the control of Listeria monocytogenes infection is controversial,
with some studies suggesting that NK cells provide protection
against Listeria and others that NK cells promote bacterial growth
[37]. Three days after challenge with Listeria, the bacterial burden
in the spleens and liver was similar between CD94-deficient and
B6 mice (Fig 4B). Similarly, control of vaccinia virus replication
was comparable in CD94-deficient and B6 mice (Fig. 4C).
Discussion
We have generated a mouse with a targeted deletion of the Klrd1
gene encoding CD94. CD94-NKG2A is the first inhibitory
receptor for MHC class I that is expressed on developing NK
cells and is the predominant inhibitory receptor expressed on fetal
NK cells [38]. Previous work proposed that CD94-NKG2A might
be necessary for self-tolerance in these developing NK cells
[39,40]. We find, however, that deletion of Klrd1 neither affected
the maturation or development of NK cells in the bone marrow,
nor did it influence the numbers or frequency of mature splenic
NK cells, suggesting other mechanisms may ensure NK self
tolerance in the absence of CD94-NKG2A. Similarly, DBA/2J
Figure 4. CD94 is not necessary for clearance of LCMV, vaccinia virus or Listeria infection. (A) B6 and CD94-deficient mice were infected
with 26105 pfu of LCMV (Armstrong strain). Spleens and livers were analyzed for LCMV titers on the indicated days. (B) B6 and CD94-deficient mice
were challenged with 16105 cfu Listeria monocytogenes. Spleens and livers were analyzed for bacterial burdens three days later. (C) B6 and CD94-
deficient mice were challenged with 56106 pfu vaccinia virus. Spleens and ovaries were analyzed for viral titers seven days later. Graphs represent the
average 6 s.e.m. of three to five animals per group per time point.
doi:10.1371/journal.pone.0015184.g004
BALB/c mice receiving the 20D5HCmIgG1-Q antibody or PBS were infected with 56104 pfu MCMV and then analyzed for viral titers three days later.
Graphs represent the average 6 s.e.m. of four or five animals per group. Not statistically significant (n.s.).
doi:10.1371/journal.pone.0015184.g003
CD94-Deficient Mice
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mice have a spontaneously arising mutation in the Klrd1 gene that
prevents expression of CD94, yet NK cells develop normally in these
mice and do not cause overt autoimmunity [24]. Compensatory
mechanisms mediated by other inhibitory receptors might facilitate
NK cell education in these CD94-deficient mice [31,32]. Loss of
CD94-NKG2A in the CD94-deficient mice might be predicted to
render the developing NK cells hypo-responsive; however, CD94-
deficient splenic NK cells produced IFN-c and degranulated at
similar frequencies to CD94Tg/– and 129/SvJ NK cells. Additionally,
mature CD94-deficient NK cells were competent to kill YAC-1 cells
in vitro and B2m2/2 splenocytes in vivo, indicating that these cells
were not impaired in their lytic functions. Depletion of CD94-
NKG2A+ NK cells was previously shown to impair rejection of
B2m2/2 splenocytes in vivo by B6 NK cells [31]. Sorted CD94– NK
cells from B6 mice were also reported to be less cytolytic against
YAC-1 targets than their CD94+ counterparts [41]. These
discrepancies between our findings and prior reports could be
accounted for by the differential Ly49 repertoire expressed by CD94-
deficient NK cells compared to B6 NK cells. Specifically, four of the
inhibitory Ly49 receptors in the 129/SvJ NK receptor haplotype
expressed by the CD94-deficient NK cells are reactive to H-2b
(Ly49G2, I, O, and V), whereas only two of the Ly49 receptors in B6
bind H-2b (Ly49C and I) [8,42,43]. This increased repertoire of H-
2b-reactive inhibitory receptors contributed by the 129/SvJ NKC
might render CD94-NKG2A redundant in the education of NK cells
expressing the 129/SvJ NKC. The lack of monoclonal antibodies
specific for 129/SvJ Ly49 receptors prevents formal testing of this
hypothesis. Additionally, in B6 mice CD94– NK cells may represent a
less mature NK cell population that CD94+ NK cells, thus
complicating comparisons between CD94–NK cells in wildtype B6
mice and CD94-deficient NK cells bearing the 129/SvJ NKC.
Despite ubiquitous expression of the CD94 transgene in CD94-
deficient mice, surface expression of CD94-NKG2 was restored in
only half of the NK cells and a small fraction of T cells and NKT
cells (similar to expression of CD94-NKG2 in wildtype mice),
indicating that transcription of NKG2A, NKG2C, and NKG2E is
likely the rate-limiting factor in CD94 surface expression.
Similarly, the expression of the CD94 transgene in DBA2/J mice,
which lack CD94 expression, restored CD94-NKG2 expression in
only a subset of NK cells [24]. The low level of CD94 surface
expression in all cells from the CD94Tg/– mice is likely due to the
CD94 transgene being expressed at a low level as a homodimer on
all cells. Crystal structures of CD94-NKG2A and CD94-NKG2C
show that both CD94 and the NKG2 receptors make contact with
HLA-E, suggesting that CD94 homodimers might bind Qa-1
[44,45,46]. The intracellular domain of CD94 consists of only 10
amino acids and lacks any known signaling domain; thus, the
CD94 homodimers in the CD94Tg/– mice are not likely to be
functional [47].
In humans, co-culture with HCMV-infected fibroblasts led to a
selective expansion of human CD94-NKG2C+ NK cells, and CD94-
NKG2C expression correlated with positive serology for HCMV,
suggesting that CD94-NKG2C may directly recognize HCMV-
infected cells [48,49,50]. MCMV is often used to model immunity to
HCMV. B6 mice express the activating Ly49H receptor, which binds
to the MCMV m157 glycoprotein expressed on the surface of
infected cells and accounts for the NK cell-mediated resistance to
MCMV in this strain [5,6]. Blocking NKG2A/C/E receptors in B6
mice did not affect control of MCMV infection. This may be due to
the strong activation via Ly49H, overriding any effect CD94-
NKG2A/C/E receptors might have had on NK cell control of
MCMV. Unlike B6 mice, BALB/c mice do not express Ly49H and
are susceptible to MCMV. Blocking NKG2A/C/E in BALB/c mice
also did not affect control of MCMV, suggesting that Ly49H did not
mask a role for CD94-NKG2A/C/E in control of MCMV. This is in
agreement with a prior report demonstrating that viral clearance
from the submandibular glands is unaltered in CD94-deficient DBA/
2J mice (which share the BALB/c Ly49 genes) compared to DBA/2J
mice expressing a CD94 transgene, despite increased expression of
Qa-1 in the submandibular glands after viral infection [51]. The 129/
SvJ allele of Ly49I expressed in CD94-deficient and CD94Tg/– mice
binds the MCMV m157 glycoprotein and might prevent NK cell
responses to MCMV-infected cells [6]. Lack of CD94 did not
enhance control of MCMV. Thus, despite potentially playing an
important role in the NK cell response to HCMV, in mice CD94-
NKG2 receptors do not appear to be essential for the NK cell
response to MCMV in the mouse strains tested, possibly due to
redundancies in the NK response to MCMV. This may be due to
different ligands for CD94-NKG2C induced by HCMV or different
peptides being presented by HLA-E during infection that alter CD94-
NKG2C activity. Additionally CD94-deficienct mice did not alter
resistance to LCMV, vaccinia virus, or Listeria monocytogenes, but might
be important for control of other pathogens. For example, CD94-
NKG2A expression on polyoma virus-specific CD8+ T cells limits
their cytolytic capacity when engaging Qa-1-expressing target cells
[52]. Thus, further studies are warranted to uncover the physiological
role of CD94-NKG2 receptors in NK cell-mediated host defense.
Materials and Methods
Mice
C57BL/6 (B6) and 129/SvJ mice purchased from the National
Cancer Institute and Jackson Labs respectively. All mice were
maintained in the specific pathogen-free animal facility of the
University of California San Francisco or Fox Chase Cancer
Center. The Fox Chase Cancer Center Institutional Animal Care
(A3285-01) and Use Committee and the UCSF Institutional
Animal Care and Use Committee (AN080996-02E) approved
animal protocols.
Generation of CD94-deficient and CD94Tg mice
A fragment of 129-strain mouse genomic DNA was isolated and
the Klrd1 gene was mapped and sequenced. Like human KLRD1
[53], the mouse gene is encoded by 6 exons. The neomycin-
resistance gene, flanked by lox sites, was used to disrupt Klrd1,
resulting in the partial elimination of exon 3 and complete removal
of exon 4. The deleted genetic segments contain the extracellular
region with the cysteine residue required for dimerization with
NKG2A, NKG2C, and NKG2E and removed a substantial
amount of the C-type lectin-like domain. Homologous recombi-
nation in 129 ES cells was confirmed by Southern blot analysis
and the neomycin-resistance gene was deleted by transient
transfection of the cells with the Cre recombinase to avoid effects
on expression of neighboring genes, sometimes caused by the
neomycin-resistance gene cassette. Chimeric mice were produced
and germline transmission was achieved. Mice were backcrossed
to C57BL/6 for 9 generations. A CD94 transgene driven by the
class I promoter/Igm enhancer [24] was injected into CD94-
deficient blastocysts to generate CD94Tg/– mice.
Antibody staining
Splenocytes were stained with anti-NKp46 (29A1.4), anti-Ly49H
(3D10), anti-Ly49C/I (5E6), anti-CD94 (18d3), anti-NKG2A/C/E
(20D5), anti-NKG2D (CX5), anti-NK1.1 (PK136), anti-TCRb
CD94-Deficient Mice
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(H57-597), anti-CD45.1 (A20), anti-CD45.2 (104), anti-CD49b
(DX5), anti-integrin aV (RMV-7), anti-CD11b (M1/70), anti-CD27
(LG3.A10), anti-H-2Kb (AF6-88.5), anti-CD69 (H1.2F3), anti-
granzyme B (GB11), anti-CD107a (1D4B) and anti-IFN-c
(XMG1.2). Anti-NKp46, anti-Ly49H, anti-CD45.1, anti-NKG2D,
anti-NKG2A/C/E, and anti-CD94 were purchased from
eBioscience. Anti-NK1.1, anti-CD45.2, anti-H-2Kb, anti-TCRb,
and anti-CD11b were purchased from BioLegend. Anti-Ly49C/I,
anti-granzyme B, anti-CD107a, anti-CD69, anti-IFN-c, anti-
integrin aV and anti-CD27 were purchased from BD Biosciences.
Antibody stimulation of NK cells
IFN-c production and degranulation were determined by
incubating 56105 splenocytes on plates coated with 10 mg/mL
of anti-NKp46 or an isotype-matched control mAb for 5 hrs in the
presence of brefeldin A and anti-CD107a. Cells were surface
stained for TCRb and DX5, and for intracellular IFN-c by using
the Intracellular Staining Kit from BD Biosciences.
NK cell-mediated cytotoxicity assay
CD94-deficient mice and wildtype 129/SvJ strain mice were
injected i.p. with 200 mg poly I:C (Sigma) in sterile PBS. After
24 hrs, splenocytes were harvested and analyzed for cytotoxicity in
a 4-hr 51Cr-release assay against YAC-1 target cells.
Rejection of B2m2/2 splenocytes
Wildtype and B2m2/2 B6 splenocytes were mixed 1:1, labeled
for ten minutes with 0.5 mM CFSE in PBS, and washed twice in
PBS. Ten million labeled splenocytes were transferred i.v. into
naı¨ve recipient mice, either untreated or depleted of NK cells by
i.p. administration of 200 mg of anti-NK1.1 (PK136) 24 hrs prior
to transfer. Twenty-four hours after transfer splenocytes from
recipients were analyzed by flow cytometry.
MCMV infections
Six to ten week-old mice were infected i.p. with 56104 pfu
MCMV (Smith strain). Two days later splenocytes were stained for
NK cell activation. For measurement of MCMV viral titers,
spleens, salivary glands and livers were collected, homogenized,
plated on M2-10B4 cells (American Type Culture Collection) in
RPMI-1640 medium without FCS and incubated for 2 h at 37uC.
RPMI-1640 medium with 10% (vol/vol) FCS and 0.75% (wt/vol)
carboxymethyl cellulose was added and samples were incubated
for 7–10 days. Plaques were visualized by staining with crystal
violet dye.
Generation of an NKG2A/C/E blocking antibody
The 20D5 monoclonal antibody reacts with NKG2A, NKG2C,
and NKG2E and blocks the binding of these receptors to Qa-1b
[17]. 20D5 is a rat IgG2a antibody that depletes NK cells when
injected in vivo. To generate a non-depleting antibody that blocks
NKG2A, NKG2C, and NKG2E, a chimeric 20D5 heavy chain
cDNA sequence was made consisting of rat 20D5 VH-CH1-hinge
cDNA and mouse IgG1 CH2-CH3 cDNA by two rounds of PCR-
generating overlapping PCR products. In order to diminish Fc
effector functions of 20D5HCmIgG1, a 20D5HCmIgG1 cDNA
sequence variant was made designated 20D5HCmIgG1-Q encod-
ing 20D5mIgG1 without a conserved N-glycosylation consensus
site. The N297Q point mutation was made by using site-directed
mutagenesis (Quickchange site-directed mutagenesis II kit, Strata-
gene). The rat-mouse 20D5HCmIgG1-Q chimeric cDNA sequenc-
es were inserted in the pEE14.4 expression vector provided by
Lonza Biologics. The resulting pEE14.4-20D5mIgG1-Q expression
plasmid, together with the rat k light chain isolated from the 20D5
hybridoma, was transfected into CHOK1SV cells (Lonza Biologics)
and stable 20D5mIgG1-Q expressing CHOK1SV clones were
selected based on MSX resistance. The 20D5mIgG1-Q antibody
was purified from cell culture supernatants using protein-A based
methods.
LCMV infections
Six to ten week-old mice were infected i.p. with 26105 pfu
LCMV (Armstrong strain). On days 1, 3, 5, 7, and 13 post-
infection spleens and livers were harvested in DME with 2% FCS
(v/v). Tissues were homogenized, plated on Vero cells (ATCC),
and overlaid with 199 media containing 0.5% agarose (w/v) and
10% FCS (v/v). Four days later plaques were visualized by
staining with neutral red.
Listeria infections
Six to ten week-old mice were infected i.p. with 105 cfu log
phase Listeria monocytogenes grown in tryptic soy broth. Three days
later spleens and livers were harvested in PBS with 0.1% (v/v) NP-
40, homogenized, and plated on BHI plates.
Vaccinia infections
Vaccinia virus (WR strain) was inoculated via the i.p. route with
500 ml PBS containing 56106 pfu virus. Following infections, mice
were observed daily for signs of disease (lethargy, ruffled hair,
weight loss, skin rash, eye secretions) and imminent death
(unresponsiveness to touch, lack of voluntary movements). For
the determination of virus titers on the indicated days post-
infection, the ovaries were removed and homogenized in medium
using a Tissue Lyser (Qiagen), and the spleens were made into a
single cell suspension between two frosted slides and resuspended
in 10 ml complete RPMI-1640 medium. One ml of the cell
suspensions was frozen and thawed three times and viral titers
determined by plaque assays on confluent BSC-1 cells using 10-
fold serial dilutions of the stocks in 0.5 ml RPMI-2.5 in six-well
plates (2 wells/dilution) for 1 h. Two ml fresh RPMI-2.5 was
added and the cells incubated at 37uC for 2–3 days. The media
was aspirated and the cells fixed and stained for 10 min with 0.1%
crystal violet in 20% ethanol. The fix/stain solution was
subsequently aspirated, the cells air-dried, the plaques counted,
and the pfu/ml in stocks were calculated accordingly.
Statistical analysis
Statistical differences in viral and bacterial titers were
determined by the unpaired, two-tailed Mann-Whitney test.
Statistical differences in IFN-c and CD107 expression were
determined by the unpaired, two-tailed Student’s t test. Statistics
were determined with Prism software (GraphPad Software, Inc.).
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